BHC Valuation

Bausch Health Companies Inc

Add to Watchlist

Advanced Chart

7.350

-0.33(-4.297%)1D

Overview
Forecast
Valuation
Earnings

BHC Relative Valuation

BHC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BHC is overvalued; if below, it's undervalued.

Historical Valuation

Bausch Health Companies Inc (BHC) is now in the Undervalued zone, suggesting that its current forward PE ratio of 1.56 is considered Undervalued compared with the five-year average of 3.43. The fair price of Bausch Health Companies Inc (BHC) is between 62.45 to 79.62 according to relative valuation methord. Compared to the current price of 7.50 USD , Bausch Health Companies Inc is Undervalued By 87.98%.

Relative Value

Fair Zone

62.45-79.62

Current Price：7.50

87.98%

Undervalued

1.49

Trailing

Forward

6.67

EV/EBITDA

Bausch Health Companies Inc. (BHC) has a current EV/EBITDA of 6.67. The 5-year average EV/EBITDA is 8.16. The thresholds are as follows: Strongly Undervalued below 6.07, Undervalued between 6.07 and 7.11, Fairly Valued between 9.21 and 7.11, Overvalued between 9.21 and 10.26, and Strongly Overvalued above 10.26. The current Forward EV/EBITDA of 6.67 falls within the Undervalued range.

7.32

EV/EBIT

Bausch Health Companies Inc. (BHC) has a current EV/EBIT of 7.32. The 5-year average EV/EBIT is 8.92. The thresholds are as follows: Strongly Undervalued below 6.42, Undervalued between 6.42 and 7.67, Fairly Valued between 10.17 and 7.67, Overvalued between 10.17 and 11.42, and Strongly Overvalued above 11.42. The current Forward EV/EBIT of 7.32 falls within the Undervalued range.

0.28

Bausch Health Companies Inc. (BHC) has a current PS of 0.28. The 5-year average PS is 0.56. The thresholds are as follows: Strongly Undervalued below -0.21, Undervalued between -0.21 and 0.17, Fairly Valued between 0.94 and 0.17, Overvalued between 0.94 and 1.33, and Strongly Overvalued above 1.33. The current Forward PS of 0.28 falls within the Historic Trend Line -Fairly Valued range.

1.66

P/OCF

Bausch Health Companies Inc. (BHC) has a current P/OCF of 1.66. The 5-year average P/OCF is 4.17. The thresholds are as follows: Strongly Undervalued below -3.33, Undervalued between -3.33 and 0.42, Fairly Valued between 7.92 and 0.42, Overvalued between 7.92 and 11.68, and Strongly Overvalued above 11.68. The current Forward P/OCF of 1.66 falls within the Historic Trend Line -Fairly Valued range.

1.99

P/FCF

Bausch Health Companies Inc. (BHC) has a current P/FCF of 1.99. The 5-year average P/FCF is 2.29. The thresholds are as follows: Strongly Undervalued below -0.46, Undervalued between -0.46 and 0.91, Fairly Valued between 3.66 and 0.91, Overvalued between 3.66 and 5.03, and Strongly Overvalued above 5.03. The current Forward P/FCF of 1.99 falls within the Historic Trend Line -Fairly Valued range.

Bausch Health Companies Inc (BHC) has a current Price-to-Book (P/B) ratio of -3.72. Compared to its 3-year average P/B ratio of -3.06 , the current P/B ratio is approximately 21.37% higher. Relative to its 5-year average P/B ratio of -11.53, the current P/B ratio is about -67.76% higher. Bausch Health Companies Inc (BHC) has a Forward Free Cash Flow (FCF) yield of approximately 40.64%. Compared to its 3-year average FCF yield of 14.26%, the current FCF yield is approximately 185.03% lower. Relative to its 5-year average FCF yield of 13.60% , the current FCF yield is about 198.89% lower.

-3.56

P/B

Median3y

-3.06

Median5y

-11.53

39.26

FCF Yield

Median3y

14.26

Median5y

13.60

Competitors Valuation Multiple

The average P/S ratio for BHC's competitors is 56.62, providing a benchmark for relative valuation. Bausch Health Companies Inc Corp (BHC) exhibits a P/S ratio of 0.28, which is -99.51% above the industry average. Given its robust revenue growth of 5.29%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BHC.N

Bausch Health Companies Inc

Cidara Therapeutics Inc

Niagen Bioscience Inc

5.71

36.84%

771.21M

Performance Decomposition

Market capitalization of BHC decreased by 5.88% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 0.22 to 27.71.

The secondary factor is the Revenue Growth, contributed 5.29%to the performance.

Overall, the performance of BHC in the past 1 year is driven by P/E Change. Which is more unsustainable.

5.29%

2.40B → 2.53B

Revenue Growth

-12750.00%

-0.04 → 5.06

Margin Expansion

12738.83%

0.22 → 27.71

P/E Change

-5.88%